Article
An NIH lupus cohort study looked at fatigue in SLE and found associations with organ damage, obesity, but does not correlate with disease activity in systemic lupus erythematosus (SLE) patients.
All News
Article
Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective and
Article
A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.
Article
Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial.
Article
Annals of Internal Medicine reports that patients with chronic low back pain (cLBP) may benefit from physical therapy (PT); but when that fails, other secondary measures (cognitive behavioral therapy (CBT) or mindfulness) may not be effective.
Article
Vitamin D deficiency or insufficiency of is highly prevalent and has been often associated with inflammatory rheumatic diseases, raising the question of whether inadequate vitamin D status contributes to immune dysregulation, incipient disease, increased disease activity, or poor skeletal outco
Article
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com
Dr. John Cush
Tweet
Advanced Practice Rheum: Still's Disease and Fever
https://t.co/P3qbGYll8y https://t.co/6EAoVWimSI
Dr. John Cush
Tweet
Chronic Low Back Pain Disappointments in a Randomized Trial
Annals of Internal Medicine reports that patients with chronic low back pain (cLBP) may benefit from physical therapy (PT); but when that fails, other secondary measures (cognitive behavioral therapy (CBT) or https://t.co/17JObbXz5U
Dr. John Cush
Tweet
Vitamin D in Rheumatic Disease - Is It Good Enough?
Vitamin D in rheumatic disease — is it sufficient? Vitamin D deficiency/insufficiency is common and linked to inflammatory rheumatic diseases, raising the question of whether low vitamin D drives immune dysregulation, disease https://t.co/CLBFii2TbR
Dr. John Cush
Tweet
🚨 SAVE THE DATE
June 3–6, 2026
RheumNow is bringing you real-time coverage of #EULAR2026
👉 Breaking data
👉 Late-breakers
👉 Global expert insights
Don’t miss a moment. #Rheumatology https://t.co/hqmIdeoS4H
Dr. John Cush
Tweet
APR: Still's Disease
Companion slide deck for the Advanced Practice Rheum: Still's Disease and Fever video, featuring Dr. Jack Cush.
https://t.co/wsUP2zEulC https://t.co/AWSNt9Uzlg
Dr. John Cush
Tweet
Influential Rheumatoid Factors (5.8.2026)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.
https://t.co/BaugLQEIai https://t.co/WdWXAfB5lk
Dr. John Cush
Tweet
Parvovirus B19 Infection - Images from JAMA Dermatology. 40yoM 2-days asymptomatic rash w/ fever to 39°C, w/ arthralgias, Rash on BL cheeks, inguinal, flanks, axilla. WBC =2K, CRP 1.24 mg/dl. Dx by PCR for parvovirus B19 DNA https://t.co/LGGnabvFvA https://t.co/yyBF9pEGls
Dr. John Cush
Tweet
Dr. Robert Terkeltaub walks through the evolution of gout at #RheumNowLive 2026.
🎧 Listen here: https://t.co/S6RXQo2Umt
#Gout #Rheumatology #MedEd https://t.co/XDbTmj3MOw
Dr. John Cush
Tweet
“60-40-20” - Ed Keystone
(rumor has it he was actually bidding on a copy of my textbook!)
Dr. John Cush
Tweet
In Still's disease, what is the primary life-threatening complication clinicians must monitor for? If you think you know the answer, prove it in this week's RheumIQ quiz at https://t.co/KVK8J2iaFQ https://t.co/O62ZpIciWW
Dr. John Cush
Tweet
24 systemic amyloidosis pts (AA type 46%, AL 29%); 62% joint pain & AM stiff, axial 37.5%, macroglossia (4 pts, 17%), carpal tunnel (12%), proteinuria > 1 gm 50%, CKD 21%, Cardiac amyloid 29%. Amyloid was secondary to Rheum Dx in 11/24. Better survival w/ AA than AL (91% vs https://t.co/hwkpeav4MQ
Dr. John Cush
Tweet
Steroids
Corticosteroids remain a cornerstone of rheumatologic therapy — rapidly effective but chronically dangerous, as their power to suppress inflammation through inhibition of prostaglandins, lipoxygenase, pro-inflammatory cytokines, and proteases comes at the cost of a https://t.co/PKdnFi1XSr
Dr. John Cush
Tweet
Have a Rheumatology question or case for Jack Cush? Record it here, and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/yyGRvXx3lL https://t.co/MgPqpaFLOc
